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Many studies showed that Topiramate (TPM) may be a useful drug in a wide spectrum of childhood epilepsies. We report a
3-month-old female with stormy onset of secondarily generalized partial seizures. She showed a high seizure frequency and
a progressive worsening electroencephalogram (EEG), despite standard antiepileptic drugs administration. TPM succeeded in
controlling seizures, even after the other drugs were discontinued. This case suggests that TPM may represent a good choice for
the treatment of partial seizures refractory to conventional drugs in infants.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Topiramate (TPM) is a sulfamate-substituted monosac-
charide that modulates the voltage-gated sodium and
calcium channels, blocks the kainate/AMPA type of
glutamate receptors and increases the GABAergic
inhibition at a unique site on the GABA receptor1, 2.
Experience in children have been limited, but TPM
has been demonstrated to be effective in children
with refractory partial seizures3, 4, Lennox–Gastaut
syndrome5, 6 and refractory infantile spasms7 as well
as severe myoclonic epilepsy in infancy8.
Here we report the experience of TPM treatment in
a 3-month-old infant with refractory seizures.
CASE REPORT
A 15-month-old female was admitted at the age of 3
months to our Department because of new onset of
partial seizures. They were characterized by paleness,
stertorous breathing, staring, sometimes conjugate
tonic deviation of eyes without a preferential side, that
often progressed to a generalized stiffness and jerks at
the forelimbs. The episodes were frequent (5–10 daily)
and had an average duration of 1–2 minutes. The fam-
ily history was unremarkable. The perinatal period
was normal. At first seizure onset, she was treated
with Phenobarbitone, obtaining only a transitory im-
provement; Diazepam at first, then Clonazepam were
been added-on. Moreover, Pyridoxine 100 mg a day
over 7 days was given, without any response. At the
time of the first admission to our Department, she
was drowsy and poorly reactive to stimuli with poor
spontaneous motility. Seizures were frequent and pre-
sented the same clinical features. Some episodes were
recorded, which corresponded to depression of EEG
activity (sometimes starting from the left hemisphere,
sometimes from the right) followed by rapid general-
ization of the abnormalities. We introduced Valproic
Acid (VPA) and continued administrating Pyridoxine,
Phenobarbitone and Clonazepam. The Griffiths De-
velopmental Scale for Children was low, documenting
a Development Quotient (DQ) of 37 (see Fig. 1). The
brain MRI was normal. A polygraphic video-EEG
recorded during sleep revealed quite good organiza-
tion with sporadic focal epileptic abnormalities, not
activated by sleep. Over the next days, seizures be-
came more frequent (up to 20 episodes daily), even
when the VPA dosage was progressively increased
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Fig. 1: Clinical and psycomotor course.
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(to 37 mg/kg/day). Moreover, the subsequent two
video-EEG recordings (1 and 2 weeks after seizure
onset) showed a progressive loss of organization with
multifocal abnormalities, very similar to a modified
hypsarhythmia. At the same time, we recorded in-
frequent spasms which corresponded to diffuse high
amplitude slow-waves. Considering the progressive
clinical and EEG worsening, we decided to reduce
the VPA dosage and to introduce TPM starting at
1.3 mg/kg/day, with daily increases of 0.3 mg/kg. This
choice allowed a quick reduction of seizure frequency
with a complete remission when she was administered
2.5 mg/kg/day of TPM. A second admission was ar-
ranged when she was 6 months old. She was seizure
free and still receiving Phenobarbitone at a low
dosage, and TPM (4 mg/kg/day). The EEG was nor-
mal. A neurological examination showed improved
responsiveness, and the DQ was 90 (see Fig. 1).
Now, at the age of 15 months, she is still receiv-
ing TPM in monotherapy (4 mg/kg/day) and is seizure
free; neurological examination and EEG are normal
and she has a DQ of 90 (see Fig. 1).
DISCUSSION
As regards the diagnosis, the early seizure onset, at
3 months of age, and the patient’s poor condition
suggested a symptomatic epilepsy. Nevertheless, the
neuroimaging was normal, metabolic disease was
investigated and excluded. Pyridoxine-dependent
epilepsy was a possible diagnosis from a clinical and
EEG point of view9, but our patient was not responsive
to the Pyridoxine administration. The multifocal inter-
ictal abnormalities and the variability of the epilepto-
genic focus (from both hemispheres) led us to consider
migrating partial seizures of infancy10. Moreover, we
observed no seizures simultaneously affecting dif-
ferent areas of the cortex, and a favourable outcome
followed, excluding this diagnosis. We considered
the hypothesis of an idiopathic partial epilepsy, sim-
ilar to those described by Watanabe and Okumura11
since the perinatal history was unremarkable and the
psychomotor development was normal before seizure
onset; however, the high seizure frequency, the oc-
currence of epileptic spasms and the progressive in-
terictal EEG worsening with modified hypsarhythmia
ruled those out. As regards the therapy, our patient
was unresponsive to conventional antiepileptic drugs:
Phenobarbitone (up to 9 mg/kg/day) and VPA (up to
37 mg/kg/day), Clonazepam (up to 0.24 mg/kg/day)
and Diazepam (up to 0.6 mg/kg/day) were ineffective.
We chose TPM given its effectiveness in control-
ling both partial and generalized seizures and spasms
and given its good safety profile. TPM efficacy in
infancy has not been described in literature. TPM
started to be effective at only 2.5 mg/kg/day and we
increased the dose to 4 mg/kg/day. After 1 year of
treatment with TPM in monotherapy, the patient was
still seizure free and we observed no adverse effects,
such as irritability, weight loss, anhydrosis or cogni-
tive deterioration. We know that a single case does
not prove TPM efficacy in infants, but we think that
further clinical reports and controlled studies of TPM
administration in infancy are needed in order to gain
better knowledge of this drug in this age group.
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